The Pancreatic Cancer Action Network is accepting applications for its 2018 Pancreatic Cancer Action Network Translational Research Grant program.
Grants of up to $500,000 over two years will be awarded for high-priority pancreatic cancer research that is poised for important translational next steps to help move scientific discovery to application in patients.
This year, PCAN has partnered with the Celgene Corporation to accelerate the development of novel therapies by establishing strong relationships between academia and industry through research grants. Funded projects will benefit from industry input and insight, leading to an accelerated translation into a therapeutic product.
Projects should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. Of particular interest are projects that fall into at least one of these three areas of research: a) immune context and tumor microenvironment interactions; (b) regulators of pathogenesis, progression and metabolism, with particular interest in epigenetic mechanisms; and (c) transcriptional networks essential for viability and maintenance of malignant phenotype.
It is anticipated that four Translational Research grants will be awarded in 2018.
To be eligible, applicants must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD or equivalent) in the biomedical sciences or in a field applicable to health science research and not currently be a candidate for a further doctoral degree. In addition, the contact principal investigator must be affiliated with an accredited academic, medical or research institution. International institutions are included.
See the PCAN website for complete program guidelines and application instructions.